申请人:Centaurus BioPharma Co., Ltd.
公开号:EP3141546A1
公开(公告)日:2017-03-15
Provided are a compound represented by formula (III) or pharmaceutically acceptable salts, solvates, active metabolites, polymorphs, esters, tautomers or prodrugs thereof, pharmaceutical compositions containing the compound represented by formula (III), and the application of the pharmaceutical compositions as selective inreversible inhibitor of Bruton's tyrosine kinase for the prevention and treatment of inflammation, autoimmune diseases (such as rheumatoid arthritis) associated with aberrant B cell proliferation and cancers.
本发明提供了一种由式(III)代表的化合物或其药学上可接受的盐、溶液剂、活性代谢物、多晶型物、酯类、同系物或原药,含有由式(III)代表的化合物的药物组合物,以及该药物组合物作为布鲁顿酪氨酸激酶选择性不可逆抑制剂在预防和治疗炎症、与 B 细胞异常增殖相关的自身免疫性疾病(如类风湿性关节炎)和癌症方面的应用。